Results 231 to 240 of about 17,703,275 (296)

Comparison between conventional, grinding, and microwave synthesis of methylpyrazoles as VEGFR-2/HSP90 dual inhibitors. [PDF]

Future Med Chem
Husseiny EM, Abdelnaby RM, Altwaijry N, Saleh A, Anwer KE.   +4 more
europepmc   +1 more source

Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model

British Journal of Pharmacology, Volume 183, Issue 12, Page 3395-3408, June 2026.
In this study, nintedanib reduced lung fibrosis in a rat double‐hit bleomycin‐induced model. Transcriptomic analysis revealed two key gene signatures related to the effect of the molecule: one involving mesenchymal cells affecting known fibrotic pathways and another linking mainly macrophages to lipid metabolism.
Martina Bonatti, Vanessa Pitozzi, Paola Caruso, Silvia Pontis, Maria Gloria Pittelli, Caterina Frati, Denise Madeddu, Federico Quaini, Costanza Anna Maria Lagrasta, Ilaria Minato, Emanuela Bocchi, Maurizio Civelli, Gino Villetti, Marcello Trevisani, Barbara Montanini   +14 more
wiley   +1 more source

Yijing Decoction improves premature ovarian failure in rats by activating VEGF/VEGFR-2/FAK pathway. [PDF]

J Ovarian Res
Gao R, Wu Y, Tang Y, Wu K, Guo B.
europepmc   +1 more source

When Binding Is Not Blockade: Interpreting IgG4+ T Cells After PD‐1 Therapy

Cancer Science, Volume 117, Issue 6, Page 1766-1768, June 2026.
IgG4 positivity on circulating T cells after PD‐1 therapy may indicate residual antibody binding rather than sustained functional PD‐1 blockade. During sequential ramucirumab plus docetaxel plus G‐CSF treatment, peripheral IgG4+ T‐cell dynamics may also be influenced by redistribution and treatment‐related confounders, limiting direct inference about ...
Man Sun, Dan Zang, Jun Chen
wiley   +1 more source

Design, synthesis, and apoptotic antiproliferative activity of novel dihydropyrimidine-5-carbonitrile/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors endowed with antioxidant activity. [PDF]

RSC Adv
Al-Wahaibi LH, Mohamed AM, Abou-Zied HA, Abdullah Alzahrani AY, Bräse S, Youssif BGM.   +5 more
europepmc   +1 more source

VEGF‐Positive Mass‐Forming Intrahepatic Cholangiocarcinoma: New Subtype Based on Radiological and Molecular Pathological Analysis

Hepatology Research, Volume 56, Issue 6, Page 976-987, June 2026.
Radiological and molecular pathological investigation of hypervascular intrahepatic cholangiocarcinoma, typically a hypovascular tumor, revealed high VEGF expression, an increase in tumor‐associated arterial vessels, and a strong correlation with favorable prognosis.
Junya Tsuzaki, Naoto Kubota, Shigeyoshi Soga, Yasuhito Arai, Tatsuhiro Shibata, Minoru Esaki, Masahiro Jinzaki, Hidenori Ojima   +7 more
wiley   +1 more source

Retraction: Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. [PDF]

RSC Adv
Patel HM, Bari P, Karpoormath R, Noolvi M, Thapliyal N, Surana S, Jain P.   +6 more
europepmc   +1 more source

Plasminogen Activator Inhibitor‐1 is Internalized by Endothelial Cells via A Pinocytosis‐Like Mechanism and Evades Degradation

The FASEB Journal, Volume 40, Issue 10, 31 May 2026.
Plasminogen activator inhibitor 1 (PAI1) is a secreted protein that also regulates intracellular processes, such as inhibition of endothelial nitric oxide synthase (eNOS). Interaction between Plasminogen Activators (PA) and PAI1 results in a covalent linkage.
Molly McAdow, Gjina Ahmetaj, Rachel Hauschel, Anne Eichmann, William Sessa   +4 more
wiley   +1 more source

Retraction: MicroRNA-497 suppresses renal cell carcinoma by targeting VEGFR-2 in ACHN cells. [PDF]

Biosci Rep
europepmc   +1 more source

Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance. [PDF]

Arch Pharm Res
Shah FH, Nam YS, Bang JY, Hwang IS, Kim DH, Ki M, Lee HW.   +6 more
europepmc   +1 more source